This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Acnatac, clindamycin with tretinoin
Description: Acnex consists of clindamycin, an antibiotic, with tretinoin, a retinoid, and is formulated as a once-daily gel. Topical combinations of an antibacterial agent with a retinoid are standard therapy for moderate-to-severe acne. Clindamycin reduces skin colonization by the bacterium Propionibacterium acnes. Tretinoin serves to reduce inflammation and normalize the maturation of the follicular epithelium.
Valeant and Meda
In August 2008, Valeant and Meda announced that the companies have agreed to form joint ventures in Australia, Canada and Mexico to develop, market and commercialize certain current and future products. The joint ventures will be majority-owned by Meda and Valeant will own a minority interest. The joint ventures will pursue the regulatory filings and manage the commercialization of the products and Valeant will participate in a profit share. The joint ventures will initially include products such as Sublinox (treatment of insomnia) and flupertine (pain treatment), with the option to include additional products in the future.
In April 2014, Meda has reached an agreement with Valeant to terminate the companies joint ventures in Canada, Mexico and Australia in the second quarter of 2014. The product rights to flupirtine, Onsolis and Sublinox are returned to Meda while Valeant will continue to run the business in Canada, including the products Palafer,...See full deal structure in Biomedtracker
Additional information available to subscribers only: